Abstract:Background: Accumulating evidence has highlighted the potential role of long non-coding RNAs (lncRNAs) in the biological behaviors of hepatocellular carcinoma (HCC). Here, we elucidated the function and possible molecular mechanisms of the effect of lncRNA-AGAP2-AS1 on the biological behaviors of HCC. Methods: EdU, Transwell and flow cytometry were used to determine proliferation, migration, invasion and apoptosis of HCC cells in vitro. The subcutaneous tumor model and lung metastasis mouse model in nude mice was established to detect tumor growth and metastasis of HCC in vivo. The direct binding of miR-16-5p to 3'UTR of ANXA11 was confirmed by luciferase reporter assay. The expression of AGAP2-AS1 and miR-16-5p in HCC specimens and cell lines were detected by real-time PCR. The correlation among AGAP2-AS1 and miR-16-5p were disclosed by a dual-luciferase reporter assay, RIP assay and biotin pull-down assay. Results: Here, we demonstrated that AGAP2-AS1 expression was up-regulated in HCC tissues and cell lines, especially in metastatic and recurrent cases. Gain- and loss-of-function experiments indicated that AGAP2-AS1 promoted cell proliferation, migration, invasion, EMT progression and inhibited apoptosis of HCC cells in vitro and in vivo. Further studies demonstrated that AGAP2-AS1 could function as a competing endogenous RNA (ceRNA) by sponging miR-16-5p in HCC cells. Functionally, gain- and loss-of-function studies showed that miR-16-5p promoted HCC progression and alteration of miR-16-5p abolished the promotive effects of AGAP2-AS1 on HCC cells. Moreover, ANXA11 was identified as direct downstream targets of miR-16-5p in HCC cells, and mediated the functional effects of miR-16-5p and AGAP2-AS1 in HCC, resulting in AKT signaling activation. Clinically, AGAP2-AS1 and miR-16-5p expression were markedly correlated with adverse clinical features and poor prognosis of HCC patients. We showed that hypoxia was responsible for the overexpression of AGAP2-AS1 in HCC. And the promoting effects of hypoxia on metastasis and EMT of HCC cells were reversed by AGAP2-AS1 knockdown. Conclusions: Taken together, this research supports the first evidence that AGAP2-AS1 plays an oncogenic role in HCC via AGAP2-AS1/miR-16-5p/ANXA11/AKT axis pathway and represents a promising therapeutic strategy for HCC patients.Funding Statement: This study was supported by grants from the National Natural Science Foundation of China (81572847, 81402039).Declaration of Interests: The authors declare that they have no competing interests.Ethics Approval Statement: The protocols for these animal experiments were approved by the Ethics Review Committee of Xi’an Jiaotong University.All procedures performed in studies involving human participants were in accordance with the ethical standards of the Research Ethics Committee of The First Affiliated Hospital of Xi’an Jiaotong University and with the 1964 Helsinki declaration and its later amendments. ALL written informed consent to participate in the study was obtained from HCC patients for samples to be collected from them

Argonaute2 Promotes Tumor Metastasis by Way of Up-Regulating Focal Adhesion Kinase Expression in Hepatocellular Carcinoma

LncRNA AY promotes hepatocellular carcinoma metastasis by stimulating ITGAV transcription.

Overexpression of Human Argonaute2 Inhibits Cell and Tumor Growth

Ago2/CAV1 interaction potentiates metastasis via controlling Ago2 localization and miRNA action

O‐GlcNAcylation Promotes the Migratory Ability of Hepatocellular Carcinoma Cells Via Regulating FOXA2 Stability and Transcriptional Activity

Retraction Note: Upregulation of Long Noncoding RNA ZEB1-AS1 Promotes Tumor Metastasis and Predicts Poor Prognosis in Hepatocellular Carcinoma

Overexpression of Eukaryotic Initiation Factor 5A2 Enhances Cell Motility and Promotes Tumor Metastasis in Hepatocellular Carcinoma

MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma.

Acetylation of AGO2 promotes cancer progression by increasing oncogenic miR-19b biogenesis

Proteomic Study Explores AGR2 As Pro-Metastatic Protein in HCC

Up-regulation of Ago2 expression in gastric carcinoma

AGO2 involves the malignant phenotypes and FAK/PI3K/AKT signaling pathway in hypopharyngeal-derived FaDu cells.

AGO1 May Influence the Prognosis of Hepatocellular Carcinoma Through TGF-β Pathway

Impaired AGO2/miR-185-3p/NRP1 Axis Promotes Colorectal Cancer Metastasis

Upregulated KPNA2 Promotes Hepatocellular Carcinoma Progression and Indicates Prognostic Significance Across Human Cancer Types

Ampli Fi Cation of Long Noncoding RNA ZFAS 1 Promotes Metastasis in Hepatocellular Carcinoma

Long Non-Coding RNA AGAP2-AS1, Functioning As a Competitive Endogenous RNA, Upregulates ANXA11 Expression by Sponging Mir-16-5p and Promotes Proliferation and Metastasis in Hepatocellular Carcinoma

LncRNA SNHG11 Promotes Proliferation, Migration, Apoptosis, and Autophagy by Regulating hsa-miR-184/AGO2 in HCC

Upregulation of Microfibrillar-Associated Protein 2 is Closely Associated with Tumor Angiogenesis and Poor Prognosis in Hepatocellular Carcinoma.

Long Non-Coding RNA CCAT2 is Associated with Poor Prognosis in Hepatocellular Carcinoma and Promotes Tumor Metastasis by Regulating Snail2-mediated Epithelial-Mesenchymal Transition

Identification of ACTG2 functions as a promoter gene in hepatocellular carcinoma cells migration and tumor metastasis